Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $14.88, but opened at $15.30. Imago BioSciences shares last traded at $15.30, with a volume of 100 shares traded.
Analysts Set New Price Targets
Separately, HC Wainwright lowered their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Stock Up 1.9 %
The business's 50 day moving average is $16.32 and its 200-day moving average is $17.09. The firm has a market capitalization of $565.85 million, a P/E ratio of -9.42 and a beta of 2.48.
Insider Activity at Imago BioSciences
In related news, insider Jennifer Peppe sold 5,598 shares of Imago BioSciences stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.41, for a total value of $108,657.18. Following the transaction, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 8,168 shares of company stock valued at $155,402 over the last three months. 14.90% of the stock is owned by insiders.Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in IMGO. Northern Trust Corp increased its stake in Imago BioSciences by 25.0% in the fourth quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after acquiring an additional 21,413 shares during the last quarter. Swiss National Bank acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $612,000. Ensign Peak Advisors Inc acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $593,000. Virtus ETF Advisers LLC acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $215,000. Finally, Citadel Advisors LLC boosted its position in Imago BioSciences by 20.1% in the fourth quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after buying an additional 410,487 shares in the last quarter. 99.50% of the stock is owned by institutional investors.
Imago BioSciences Company Profile
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Read More
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.